{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Reasons for the early closure of a study site by the Sponsor or Investigator may include but are', 'not limited to:', 'Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC', \"or local health authorities, the Sponsor's procedures, or GCP guidelines\", 'Inadequate recruitment of patients by the Investigator', 'Discontinuation of further study intervention development', '9.2.', 'Data Quality Control and Quality Assurance', '9.2.1.', 'Data Handling', 'Source documents provide evidence for the existence of the patient and substantiate the integrity', \"of the data collected. Source documents are filed at the Investigator's site.\", 'Data reported or entered in the eCRF that are transcribed from source documents must be', 'consistent with the source documents or the discrepancies must be explained. The Investigator', 'may need to request previous medical records or transfer records, depending on the study. Also,', 'current medical records must be available.', 'All patient data relating to the study will be recorded on printed or eCRF unless transmitted to', 'the Sponsor or designee electronically (eg, laboratory data). The Investigator is responsible for', 'verifying that data entries are accurate and correct by physically or electronically signing the', 'eCRF.', 'The Investigator must maintain accurate documentation (source data) that supports the', 'information entered in the eCRF.', 'The Investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory', 'agency inspections and provide direct access to source data documents.', 'The Sponsor or designee is responsible for the data management of this study including quality', 'checking of the data.', '9.2.2.', 'Study Monitoring', 'Study monitors will perform ongoing source data verification to confirm that data entered into', 'the eCRF by authorized site personnel are accurate, complete, and verifiable from source', 'documents; that the safety and rights of patients are being protected; and that the study is being', 'conducted in accordance with the currently approved protocol and any other study agreements,', 'ICH GCP, and all applicable regulatory requirements.', 'Records and documents, including signed ICFs, pertaining to the conduct of this study must be', 'retained by the Investigator for 15 years after study completion unless local regulations or', 'institutional policies require a longer retention period. No records may be destroyed during the', 'retention period without the written approval of the Sponsor. No records may be transferred to', 'another location or party without written notification to the Sponsor.', 'Property of the Sanofi Group - strictly confidential', '72', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '9.2.3.', 'Audits and Inspections', 'Periodically, the Sponsor or its authorized representatives audit clinical investigative sites as an', 'independent review of core trial processes and documents to determine whether these activities', 'were conducted, and data were recorded, analyzed, and accurately reported according to the', 'protocol, GCP guidelines of the ICH, and any applicable regulatory requirements. A regulatory', 'authority, an IEC, or an IRB may visit the site to perform audits or inspections, including source', 'data verification. The Investigator should contact the Sponsor, or its designee, immediately if', 'contacted by a regulatory agency, an IEC or an IRB about an inspection.', '9.3.', 'Publication Policy', 'The results of this study may be published or presented at scientific meetings. If this is foreseen,', 'the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.', 'This allows the Sponsor to protect proprietary information and to provide comments.', 'The Sponsor will comply with the requirements for publication of study results. In accordance', 'with standard editorial and ethical practice, the Sponsor will generally support publication of', 'multicenter studies only in their entirety and not as individual site data. In this case, a', 'coordinating Investigator will be designated by mutual agreement.', 'Authorship will be determined by mutual agreement and in line with International Committee of', 'Medical Journal Editors authorship requirements.', '9.4.', 'Dissemination of Clinical Study Data', 'Sanofi shares information about clinical trials and results on publically accessible websites,', 'based on company commitments, international and local legal and regulatory requirements, and', 'other clinical trial disclosure commitments established by pharmaceutical industry associations.', 'These websites include www.clinicaltrials.gov www.clinicaltrialregister.eu, and', 'www.sanofi.com as well as some national registries.', 'In addition, results from clinical trials in patients are required to be submitted to peer-reviewed', 'journals following internal company review for accuracy, fair balance and intellectual property.', 'For those journals that request sharing of the analyzable data sets that are reported in the', 'publication, interested researchers are directed to submit their request to', 'www.clinicalstudydatarequest.com.', 'Individual patient data and supporting clinical documents are available for request at', 'www.clinicalstudydatarequest.com. While making information available we continue to protect', 'the privacy of patients in our clinical trials. Details on data sharing criteria and process for', 'requesting access can be found at this web address: www.clinicalstudydatarequest.com', 'Property of the Sanofi Group - strictly confidential', '73', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}